MAIA reports OS >2 years for 8 NSCLC patients; 1 at 33 months in 3L

MAIA Biotechnology, Inc.

Eight patients treated with ateganosine + cemiplimab in Phase 2 THIO-101 trial had overall survival exceeding 24 months.
One 3rd-line patient survived 33 months vs. expected 5.8 months; four 2nd-line patients survived >30 months vs. SOC 10.5 months.
All patients had failed prior checkpoint inhibitor therapy; 5 of 8 patients have ongoing survival follow-up.
Phase 3 pivotal trial and Part C expansion (up to 48 patients in Asia/Europe) are enrolling.
Press release references a $50B+ global immunotherapy market as target opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.